Management of Plaque Psoriasis in Adults: Clinical Utility of Tapinarof Cream

References

• Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–946. doi:10.1001/jamadermatol.2021.2007
   PubMed Web of Science ®Google Scholar
• Yan D, Blauvelt A, Dey AK, et al. New frontiers in psoriatic disease research, part II: comorbidities and targeted therapies. J Invest Dermatol. 2021;141(10):2328–2337. doi:10.1016/j.jid.2021.02.743
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315. doi:10.1016/S0140-6736(20)32549-6
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Tan MH, Meador SL, Singer G. Limited application of fluticasone propionate ointment, 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol. 2001;44(1):77–82. doi:10.1067/mjd.2001.110046
   PubMed Web of Science ®Google Scholar
• Keam SJ. Tapinarof cream 1%: first approval. Drugs. 2022;82(11):1221–1228. doi:10.1007/s40265-022-01748-6
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent. J Am Acad Dermatol. 2021;84(4):1059‐1067. doi:10.1016/j.jaad.2020.10.085
   PubMed Web of Science ®Google Scholar
• Stevens EA, Mezrich JD, Bradfield CA. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology. 2009;127(3):299–311. doi:10.1111/j.1365-2567.2009.03054.x
   PubMed Web of Science ®Google Scholar
• Fernández-Gallego N, Sánchez-Madrid F, Cibrian D. Role of AHR ligands in skin homeostasis and cutaneous inflammation. Cells. 2021;10(11):3176. doi:10.3390/cells10113176
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Vázquez C, Quintana FJ. Regulation of the immune response by the Aryl hydrocarbon receptor. Immunity. 2018;48:19–33. doi:10.1016/j.immuni.2017.12.012
   PubMed Web of Science ®Google Scholar
• Esser C, Bargen I, Weighardt H, Haarmann-Stemmann T, Krutmann J. Functions of the aryl hydrocarbon receptor in the skin. Semin Immunopathol. 2013;35:677–691. doi:10.1007/s00281-013-0394-4
   PubMed Web of Science ®Google Scholar
• Sutter C, Yin H, Li Y, et al. EGF receptor signaling blocks aryl hydrocarbon receptor-mediated transcription and cell differentiation in human epidermal keratinocytes. Proc Natl Acad Sci USA. 2009;106:4266–4271. doi:10.1073/pnas.0900874106
   PubMed Web of Science ®Google Scholar
• Haarmann-Stemmann T, Esser C, Krutmann J. The janus-faced role of aryl hydrocarbon receptor signaling in the skin: consequences for prevention and treatment of skin disorders. J Invest Dermatol. 2015;135(11):2572–2576. doi:10.1038/jid.2015.285
   PubMed Web of Science ®Google Scholar
• Denison MS, Soshilov AA, He G, DeGroot DE, Zhao B. Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci. 2011;124(1):1–22. doi:10.1093/toxsci/kfr218
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Martora F, Picone V, Morelli P, Patruno C. Role of aryl hydrocarbon receptor activation in inflammatory chronic skin diseases. Cells. 2021;10(12):3559. doi:10.3390/cells10123559
   PubMed Web of Science ®Google Scholar
• Furue M, Tsuji G, Mitoma C, et al. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci. 2015;80:83–88. doi:10.1016/j.jdermsci.2015.07.011
   PubMed Web of Science ®Google Scholar
• Frauenstein K, Sydlik U, Tigges J, et al. Evidence for a novel anti-apoptotic pathway in human keratinocytes involving the aryl hydrocarbon receptor, E2F1, and checkpoint kinase 1. Cell Death Differ. 2013;20(10):1425–1434. doi:10.1038/cdd.2013.102
   PubMed Web of Science ®Google Scholar
• Murphy KA, Villano CM, Dorn R, White LA. Interaction between the aryl hydrocarbon receptor and retinoic acid pathways increases matrix metalloproteinase-1 expression in keratinocytes. J Biol Chem. 2004;279(24):25284–25293. doi:10.1074/jbc.M402168200
   PubMed Web of Science ®Google Scholar
• Ono Y, Torii K, Fritsche E, et al. Role of the aryl hydrocarbon receptor in tobacco smoke extract-induced matrix metalloproteinase-1 expression. Exp Dermatol. 2013;22(5):349–353. doi:10.1111/exd.12148
   PubMed Web of Science ®Google Scholar
• Pollet M, Shaik S, Mescher M, et al. The AHR represses nucleotide excision repair and apoptosis and contributes to UV-induced skin carcinogenesis. Cell Death Differ. 2018;25:1823–1836. doi:10.1038/s41418-018-0160-1
   PubMed Web of Science ®Google Scholar
• Beranek M, Fiala Z, Kremlacek J, et al. Serum levels of aryl hydrocarbon receptor, cytochromes P450 1A1 and 1B1 in patients with exacerbated psoriasis vulgaris. Folia Biol. 2018;64:97–102.
   PubMed Web of Science ®Google Scholar
• Ehrlich AK, Pennington JM, Bisson WH, Kolluri SK, Kerkvliet NI. TCDD, FICZ, and other high affinity ahr ligands dose-dependently determine the fate of CD4+ T cell differentiation. Toxicol Sci. 2017;161:310–320. doi:10.1093/toxsci/kfx215
   Web of Science ®Google Scholar
• Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi:10.1016/S0140-6736(21)00184-7.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Duarte JH, Ahlfors H, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity. 2014;40(6):989–1001. doi:10.1016/j.immuni.2014.04.019
   PubMed Web of Science ®Google Scholar
• van den Bogaard EH, Bergboer JG, Vonk-Bergers M, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013;123(2):917–927. doi:10.1172/JCI65642
   PubMed Web of Science ®Google Scholar
• Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110–2119. doi:10.1016/j.jid.2017.05.004
   PubMed Web of Science ®Google Scholar
• Haarmann-Stemmann T, Sutter TR, Krutmann J, Esser C. The mode of action of tapinarof may not only depend on the activation of cutaneous aryl hydrocarbon receptor signaling but also on its antimicrobial activity. J Am Acad Dermatol. 2021;85(1):e33–e34. doi:10.1016/j.jaad.2021.01.103
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:105906.
   Google Scholar
• CASP CHECKLISTS - CASP - Critical Appraisal Skills Programme. Available from: https://casp-uk.net/casp-tools-checklists/. Accessed June 21, 2023.
   Google Scholar
• Bissonnette R, Vasist LS, Bullman JN, Collingwood T, Chen G, Maeda-Chubachi T. Systemic pharmacokinetics, safety, and preliminary efficacy of topical AhR agonist tapinarof: results of a Phase 1 study. Clin Pharmacol Drug Dev. 2018;7(5):524–531. doi:10.1002/cpdd.439
   PubMed Web of Science ®Google Scholar
• Jett J, McLaughlin M, Wilson T, et al. Dermal safety of tapinarof cream 1%: results from 4 phase 1 trials. J Drugs Dermatol. 2022;21(10):1084–1090. doi:10.36849/JDD.6627
   PubMed Web of Science ®Google Scholar
• Alex A, Frey S, Angelene H, et al. In situ biodistribution and residency of a topical anti-inflammatory using fluorescence lifetime imaging microscopy. Br J Dermatol. 2018;179(6):1342–1350. doi:10.1111/bjd.16992
   PubMed Web of Science ®Google Scholar
• Jett J, McLaughlin M, Lee M, et al. Maximal use study of tapinarof cream 1% in subjects with extensive plaque psoriasis. SKIN J Cutan Med. 2020;4(6):s74. doi:10.25251/skin.4.supp.74
   Google Scholar
• Robbins K, Bissonnette R, Maeda-Chubachi T, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714–721. doi:10.1016/j.jaad.2018.10.037
   PubMed Web of Science ®Google Scholar
• Gold LS, Bhatia N, Tallman AM, Rubenstein D. Secondary efficacy outcomes from a phase 2b, randomized dose-finding study of tapinarof cream for the treatment of plaque Psoriasis. J Psoriasis Psoriatic Arthritis. 2019;4(3):162–163.
   Google Scholar
• Lebwohl M, Del Rosso JQ, Hong C-H, Tailman AM, Kircik L. Tapinarof cream for the treatment of plaque psoriasis: efficacy and safety by baseline disease characteristics and skin type in a phase 2b randomized study. SKIN J Cutan Med. 2020;4(5):s30. doi:10.25251/skin.4.supp.30
   Google Scholar
• Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219–2229. doi:10.1056/NEJMoa2103629
   PubMed Web of Science ®Google Scholar
• Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800–806. doi:10.1016/j.jaad.2022.06.1171
   PubMed Web of Science ®Google Scholar
• Bagel J, Gold LS, Del Rosso J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023;89(23):936–944.
   PubMedGoogle Scholar
• Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26:61‐67. doi:10.1111/j.1468-3083.2012.04525.x
   Web of Science ®Google Scholar
• Castela E, Archier E, Devaux S, et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):36–46. doi:10.1111/j.1468-3083.2012.04522.x
   PubMedGoogle Scholar
• Bissonnette R, Gold LS, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy. J Am Acad Dermatol. 2021;85(1):e39–e40. doi:10.1016/j.jaad.2021.03.006
   PubMed Web of Science ®Google Scholar